Stock Track | FOSUN PHARMA Soars 5.11% on Strong Q1-Q3 Results and Advancing Product Pipeline

Stock Track

Oct 31

FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive financial results for the first nine months of 2025 and positive developments in its innovative product pipeline.

Despite a 4.91% year-on-year decrease in revenue to RMB29.39 billion, FOSUN PHARMA reported a substantial 25.5% increase in net profit attributable to shareholders, reaching RMB2.52 billion. The company's basic earnings per share stood at RMB0.95. This robust profit growth was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets, demonstrating the company's strategic focus on core operations.

Investors are also optimistic about FOSUN PHARMA's advancing innovative product pipeline. In September 2025, the company's novel small-molecule CDK4/6 inhibitor FCN-437c received approval for an additional indication in China. Furthermore, HLX14, a denosumab biosimilar, secured approvals for launch in both the U.S. and EU markets. The company's FKC889 (brexucabtagene autoleucel injection) has also made progress, with its domestic marketing application accepted by China's NMPA. Analysts from Guotai Junan Securities believe that the sequential launch of these innovative drugs will drive revenue recovery, contributing to the positive market sentiment surrounding FOSUN PHARMA.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1162142034"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162142034\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162142034?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162142034","market":"nz","top_or_hot":-1,"title":"Stock Track | FOSUN PHARMA Soars 5.11% on Strong Q1-Q3 Results and Advancing Product Pipeline","media":"Stock Track","content":"<p>FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive financial results for the first nine months of 2025 and positive developments in its innovative product pipeline.</p>\n\n<p>Despite a 4.91% year-on-year decrease in revenue to RMB29.39 billion, FOSUN PHARMA reported a substantial 25.5% increase in net profit attributable to shareholders, reaching RMB2.52 billion. The company's basic earnings per share stood at RMB0.95. This robust profit growth was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets, demonstrating the company's strategic focus on core operations.</p>\n\n<p>Investors are also optimistic about FOSUN PHARMA's advancing innovative product pipeline. In September 2025, the company's novel small-molecule CDK4/6 inhibitor FCN-437c received approval for an additional indication in China. Furthermore, HLX14, a denosumab biosimilar, secured approvals for launch in both the U.S. and EU markets. The company's FKC889 (brexucabtagene autoleucel injection) has also made progress, with its domestic marketing application accepted by China's NMPA. Analysts from Guotai Junan Securities believe that the sequential launch of these innovative drugs will drive revenue recovery, contributing to the positive market sentiment surrounding FOSUN PHARMA.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | FOSUN PHARMA Soars 5.11% on Strong Q1-Q3 Results and Advancing Product Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | FOSUN PHARMA Soars 5.11% on Strong Q1-Q3 Results and Advancing Product Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive financial results for the first nine months of 2025 and positive developments in its innovative product pipeline.</p>\n\n<p>Despite a 4.91% year-on-year decrease in revenue to RMB29.39 billion, FOSUN PHARMA reported a substantial 25.5% increase in net profit attributable to shareholders, reaching RMB2.52 billion. The company's basic earnings per share stood at RMB0.95. This robust profit growth was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets, demonstrating the company's strategic focus on core operations.</p>\n\n<p>Investors are also optimistic about FOSUN PHARMA's advancing innovative product pipeline. In September 2025, the company's novel small-molecule CDK4/6 inhibitor FCN-437c received approval for an additional indication in China. Furthermore, HLX14, a denosumab biosimilar, secured approvals for launch in both the U.S. and EU markets. The company's FKC889 (brexucabtagene autoleucel injection) has also made progress, with its domestic marketing application accepted by China's NMPA. Analysts from Guotai Junan Securities believe that the sequential launch of these innovative drugs will drive revenue recovery, contributing to the positive market sentiment surrounding FOSUN PHARMA.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1162142034","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162142034","pubTimestamp":1761877618,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"个股赛道|Q1-Q3业绩强劲、产品管线推进，复星医药大涨5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"FOSUN PHARMA (02196) is experiencing a significant surge in its stock price, soaring 5.11% during Friday's trading session. The pharmaceutical giant's shares are rallying on the back of impressive financial results for the first nine months of 2025 and positive developments in its innovative product pipeline.\nDespite a 4.91% year-on-year decrease in revenue to RMB29.39 billion, FOSUN PHARMA reported a substantial 25.5% increase in net profit attributable to shareholders, reaching RMB2.52 billion. The company's basic earnings per share stood at RMB0.95. This robust profit growth was primarily driven by gains from the divestment of remaining equity in United Family Healthcare and other non-core assets, demonstrating the company's strategic focus on core operations.\nInvestors are also optimistic about FOSUN PHARMA's advancing innovative product pipeline. In September 2025, the company's novel small-molecule CDK4/6 inhibitor FCN-437c received approval for an additional indication in China. Furthermore, HLX14, a denosumab biosimilar, secured approvals for launch in both the U.S. and EU markets. The company's FKC889 (brexucabtagene autoleucel injection) has also made progress, with its domestic marketing application accepted by China's NMPA. Analysts from Guotai Junan Securities believe that the sequential launch of these innovative drugs will drive revenue recovery, contributing to the positive market sentiment surrounding FOSUN PHARMA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}